Effect of raloxifene on bone metabolism, lipid profile and glucose metabolism in postmenopausal women with type 2 diabetes mellitus

Effect of raloxifene on bone metabolism, lipid profile and glucose metabolism in postmenopausal women with type 2 diabetes mellitus - Effect of raloxifene on bone metabolism, lipid profile, and glucose metabolism in postmenopausal women with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004399

Enrollment

150

Registered

2010-12-01

Start date

2005-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

No therapy Alfacalcidol Raloxifene 60 mg/day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: postmenopausal (more than 2 years) women with type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: (1)history of phlebothrombosis (2) bed-ridden people (3)Anti-phospholipid antibody syndrome; (4)history of hypersensitivity to raloxifene or alfacalcidol (5)With effective drug of bone metabolism(bisphosphonates, vitaminK, estrogen, calcium, anabolic steroid, sex hormones)

Design outcomes

Primary

Measure	Time frame
Change of LDL-C before and after 6 months treatment	—

Countries

Japan

Contacts

Public ContactYosuke Okada

University of Occupational and Environmental Health, School of Medicine, Japan The First Department of Internal Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026